Leading-edge genomics CRO adds services for human clinical samples following venture capital investment as part of expanding biotech hub
Eremid Genomic Services, LLC (“Eremid”) announces that it has been granted a Clinical Laboratory Improvement Amendments (CLIA) accreditation for its new laboratory dedicated to analyzing human clinical samples. Founded this year following acquisition by venture capital firm, Coddle Creek Capital (“CCC”), adding CLIA services highlights the impact of CCC’s investment in Eremid and its commitment to expand services for clinical as well as research clients. The new CLIA-accredited laboratory will serve clinical and direct-to-consumer clients with best-in-class genomics analysis, delivering the exceptional quality data and service required to progress their products in human health and longevity.
Eremid was established to deliver on the increasing demand for high-end genomics research, and customers already benefit from the expertise of its world-class scientific staff and access to the latest generation of genomics instruments and automation. The company has also recently announced the opening of the Graham Genomics Laboratory, supporting a unique undergraduate genomics program from Catawba College. Now, the high-complexity CLIA-certified clinical genomics lab adds a third aspect to Eremid’s offering, enabling clinical researchers to access the same expertise and an expanding range of analytical services for human clinical samples.
“We take pride in delivering scientific excellence at Eremid, and it is gratifying to know our processes meet the rigorous standards required to receive CLIA-accreditation,” says Julian Curaba, PhD, CSO. “Our new cutting-edge lab brings with it a host of new possibilities for our customers. We are excited to now partner with clinical researchers and commercial enterprises to develop and offer a range of genomics-based assays for clinical samples.”
The Eremid team has always been dedicated to nurturing understanding of genomics, one of the most promising sources of scientific discoveries in the foreseeable future. With this new CLIA-certified laboratory, the company is fully equipped to offer a unique set of capabilities to train students, support researchers, and improve health through genomics-based diagnostics.
CLIA-certified laboratories like Eremid’s (CLIA ID Number 34D2269577) are inspected, managed, and regulated by the Centers for Medicare and Medicaid Services, as mandated by US Code of Federal Regulations (CFR 42 Part 493.2). Meeting the standards for certification ensures CLIA-certified laboratories offer a superior level of accuracy, reliability, and consistency in clinical assays conducted.
About Eremid Genomic Services, LLC
Eremid Genomic Services is a high complexity genomics contract research organization, focusing on science that influences human health and longevity. The company offers specialist expertise in human health, nutrition, and agbiotech, delivering high quality research-enhancing data through customized, collaborative projects. Eremid has invested in world-class scientific staff, and cutting-edge genomic instrumentation and automation to create a unique offering that meets the increasing demands for higher data quality, reliability, and accuracy in genomics research. The company forms the cornerstone of a biotech hub based on the North Carolina Research Campus, offering collaboration and partnership opportunities, and serving both the local and wider scientific communities. For more information, visit https://eremid.com.
About Coddle Creek Capital
Coddle Creek Capital is a life science venture capital firm focused on evaluating academic IP and initiating the first commercial efforts including corporate formation, seed investment, commercial management and capital raising. Sectors of investment include genomics, nutrition, oncology, immunology, microbiome and neurology. The firm focuses on commercializing innovations in the underserved markets of New Mexico and North Carolina. It embraces companies that invest in exceptional teams and big ideas that capitalize on emerging trends in the healthcare landscape. The fund invests in early-stage growth companies that have demonstrated scientific proof-of-concept and are looking to demonstrate commercial proof-of-concept.